Artificial Intelligence-assisted Evaluation of Pulmonary HYpertension
Artificial Intelligence-Assisted Evaluation of Pulmonary Hypertension
Chinese Pulmonary Vascular Disease Research Group
2,000 participants
Jun 1, 2022
OBSERVATIONAL
Conditions
Summary
Pulmonary hypertension represents a challenging and heterogeneous condition that is associated with high mortality and morbidity if left untreated. Artificial intelligence is used to study and develop theories and methods that simulate and extend human intelligence, which is being applied in fields related to cardiovascular diseases. The study intends to combine multimodal clinical data of patients who undergo right heart catheterization at Fuwai Hospital with artificial intelligence techniques to create programs that can screen and diagnose pulmonary hypertension.
Eligibility
Inclusion Criteria2
- Age ≥18 years old
- Patients previously received chest X-ray, electrocardiography, echocardiography, other routine examinations, and RHC at the Fuwai Hospital, CAMS \& PUMC, Beijing, China
Exclusion Criteria3
- Patients without RHC
- The quality of routine examinations and RHC cannot meet the requirement for further analysis
- Severe loss of results of routine examinations (chest X-ray, electrocardiography, echocardiography, etc.)
Interventions
RHC is commonly used essential test to make gold-standard diagnosis of PH with mPAP \>20 mmHg. All multimodal data from patients eligible for inclusion would be randomly assigned to development datasets (70% of the study population) to train the artificial intelligence models for the detection of PH, which would be validated and tested by other datasets (30% of the study population).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05566002